Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director | June 08, 2023 | June 12, 2023 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.67 · Expires 2033-06-08 | Direct | 16,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.
Intellia Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,716 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 4,425 · Balance 11,716 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2033-06-13 | Direct | 6,473 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 6,473 · Balance 6,473 F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date January 09, 2024 · Filed March 15, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-03-15. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 927,013 |
Last balance in matching sequence
After 2024-01-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-01-09 · Grant · Acquired 57,620 · Balance 995,492 F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 2 · 2024-01-09 · Tax withholding · Disposed 36,865 · Balance 958,627 F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. Row 3 · 2024-01-10 · Sale · Disposed 31,614 · Balance 927,013 F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 11, 2021 Filed Oct 13, 2021 20:15 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 2,500 | $18.83 | $47,075.00 |
DisclosureSEC source: 0001209191-21-060359 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.83 | $0.00 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 10,000 shares Expires 2030-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 12,666 shares as of October 5, 2021. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 200 | $132.84 | $26,568.00 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · nonDerivative · entry 6 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,846 | $131.74 | $243,192.04 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · nonDerivative · entry 5 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.445 to $132.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 3,759 | $130.92 | $492,128.28 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · nonDerivative · entry 4 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,140 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.445 to $131.42, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 2,915 | $129.88 | $378,600.20 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,899 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.28 to $130.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,280 | $128.83 | $164,902.40 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,814 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.09 to $129.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:41 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | Exercise / conversionCommon Stock | 10,000 | $18.83 | $188,300.00 |
DisclosureSEC source: 0001209191-21-059960 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 22:59 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,500 | $10.00 | $75,000.00 |
DisclosureSEC source: 0001209191-21-059150 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 832,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 21:27 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-056689 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,935 Underlying: Common Stock · 22,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 21:27 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,000 | $11.08 | $243,828.20 |
DisclosureSEC source: 0001209191-21-056689 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.83 to $11.18 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 21:27 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,000 | $4.38 | $96,360.00 |
DisclosureSEC source: 0001209191-21-056689 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 3,700 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001209191-21-055207 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,739 Underlying: Common Stock · 3,700 shares Expires 2024-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 1,538 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-21-055207 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,538 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 5,238 | $12.02 | $62,944.00 |
DisclosureSEC source: 0001209191-21-055207 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.00 to $12.08 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 3,700 | $3.82 | $14,134.00 |
DisclosureSEC source: 0001209191-21-055207 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 22:45 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 1,538 | $3.53 | $5,429.14 |
DisclosureSEC source: 0001209191-21-055207 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 7, 2021 22:55 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,500 | $11.50 | $86,250.00 |
DisclosureSEC source: 0001209191-21-055060 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 839,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.29 to $11.69 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-052357 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,935 Underlying: Common Stock · 22,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,000 | $10.27 | $225,918.00 |
DisclosureSEC source: 0001209191-21-052357 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.20 to $10.39 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:36 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,000 | $4.38 | $96,360.00 |
DisclosureSEC source: 0001209191-21-052357 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2021 Filed Aug 10, 2021 00:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-050504 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,935 Underlying: Common Stock · 22,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| August 05, 2021 Filed Aug 10, 2021 00:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 37,000 | $10.03 | $371,047.10 |
DisclosureSEC source: 0001209191-21-050504 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.10 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2021 Filed Aug 10, 2021 00:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,000 | $4.38 | $96,360.00 |
DisclosureSEC source: 0001209191-21-050504 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2021 Filed Jul 15, 2021 01:08 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 14,885 | $9.31 | $138,652.29 |
DisclosureSEC source: 0001209191-21-046711 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.17 to $9.59 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:57 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 3,382 | $0.00 Strike: $83.59 | $0.00 |
DisclosureSEC source: 0001209191-21-043366 · doc4.xml · derivative · entry 2 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382 Underlying: Common Stock · 3,382 shares Expires 2031-06-22 F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 21:57 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 2,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043366 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 142,872 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 11 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,537 Underlying: Common Stock · 142,872 shares Expires 2030-01-02 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 216,351 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 10 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,775 Underlying: Common Stock · 216,351 shares Expires 2029-01-02 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 131,580 | $0.00 Strike: $15.67 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 9 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,496 Underlying: Common Stock · 131,580 shares Expires 2028-01-03 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 6,889 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 8 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,596 Underlying: Common Stock · 6,889 shares Expires 2027-01-03 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 250,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 7 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2026-01-04 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $15.96 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 230,000 shares Expires 2025-06-01 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 16, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GiftStock Options (right to buy) · Derivative | 230,000 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 230,000 shares Expires 2025-01-02 F4 · kind: The gift of vested options reported on this Form 4 were made to the John F. Crowley 2021 Family Trust for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the trust. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,935 Underlying: Common Stock · 22,000 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,000 | $10.26 | $225,632.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,230 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.13 to $10.69 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2021 Filed Jun 18, 2021 00:06 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,000 | $4.38 | $96,360.00 |
DisclosureSEC source: 0001209191-21-041766 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 1,443 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-039297 · doc4.xml · derivative · entry 6 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,935 Underlying: Common Stock · 1,443 shares Expires 2022-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 20,557 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001209191-21-039297 · doc4.xml · derivative · entry 5 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,557 shares Expires 2022-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 29,500 | $10.01 | $295,191.75 |
DisclosureSEC source: 0001209191-21-039297 · doc4.xml · nonDerivative · entry 3 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,230 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.0650 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 1,443 | $4.38 | $6,320.34 |
DisclosureSEC source: 0001209191-21-039297 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 23:31 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 20,557 | $6.45 | $132,592.65 |
DisclosureSEC source: 0001209191-21-039297 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 21:59 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,500 | $10.28 | $77,088.75 |
DisclosureSEC source: 0001209191-21-030438 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,730 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.25 to $10.36 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:37 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,683 | $10.01 | $76,897.61 |
DisclosureSEC source: 0001209191-21-028354 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,230 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.035 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionStock Options (right to buy) · Derivative | 22,000 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001209191-21-027388 · doc4.xml · derivative · entry 4 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,557 Underlying: Common Stock · 22,000 shares Expires 2022-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of these options were fully vested and exercisable as of the transaction date. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 22,000 | $10.09 | $222,085.60 |
DisclosureSEC source: 0001209191-21-027388 · doc4.xml · nonDerivative · entry 2 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,913 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.18 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:21 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | Exercise / conversionCommon Stock | 22,000 | $6.45 | $141,900.00 |
DisclosureSEC source: 0001209191-21-027388 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 00:04 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 78,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026163 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 899,913 F1 · security: Granted in the form of Restricted Stock Units for the achievement of the 2019 PRSU Revenue goal. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock. The Restricted Stock Units will vest on December 31, 2021, subject to the reporting person's continued service with the Company. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:17 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,500 | $10.00 | $75,000.00 |
DisclosureSEC source: 0001209191-21-025370 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,524 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 21:11 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | SaleCommon Stock | 7,682 | $10.29 | $79,060.84 |
DisclosureSEC source: 0001209191-21-022894 · doc4.xml · nonDerivative · entry 1 Crowley John F · CIK 0001400973 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 829,024 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.23 to $10.35 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.